首页|期刊导航|广东医学|弥漫性大B细胞淋巴瘤中Syndecan-2的表达及意义

弥漫性大B细胞淋巴瘤中Syndecan-2的表达及意义OA

Clinical and prognostic significance of Syndecan-2 expression in diffuse large B-cell lymphoma

中文摘要英文摘要

目的 探讨多配体蛋白聚糖-2(Syndecan-2,SDC2)在弥漫性大B细胞淋巴瘤(DLBCL)中的表达、临床病理意义、预后价值及其与肿瘤微环境(TME)的关联.方法 基于GEO数据库(GSE53786)的转录组数据,分析SDC2的表达与预后及TME评分.收集137例DLBCL患者组织样本,通过免疫组化检测SDC2蛋白表达,分析其与临床病理特征、总生存期(OS)及免疫细胞浸润的关系.结果 生物信息学分析显示,SDC2高表达是DLBCL患者总生存期的独立保护因素(HR=0.40,95%CI:0.23~0.72,P=0.002),且其表达与间质评分显著正相关(R=0.621,P<0.001).免疫组化验证证实,SDC2高表达组患者OS更优(P=0.021),并且是独立的预后保护因素(多因素分析HR=0.469,95%CI:0.226~0.974,P=0.042).此外,SDC2高表达组呈现出CD68+巨噬细胞浸润减少的趋势.结论 SDC2是DLBCL一个独立的保护性预后标志物,其高表达预示更长的总生存期.SDC2的预后价值可能与其调节肿瘤微环境,特别是影响间质成分有关.

Objective To investigate the expression of Syndecan-2(SDC2)in diffuse large B-cell lymphoma(DLBCL)and to evaluate its clinicopathological significance,prognostic value,and association with the tumor microenvi-ronment(TME).Methods Transcriptomic data from the Gene Expression Omnibus(GEO)dataset(GSE53786)were analyzed to assess the relationship between SDC2 expression,patient prognosis,and tumor microenvironment scores.In addition,tissue samples from 137 patients with DLBCL were collected,and SDC2 protein expression was evaluated by im-munohistochemistry.Associations between SDC2 expression and clinicopathological characteristics,overall survival(OS),and immune cell infiltration were further analyzed.Results Bioinformatics analysis revealed that high SDC2 expression was an independent protective factor for overall survival in patients with DLBCL(HR=0.40,95%CI:0.23-0.72,P=0.002).Moreover,SDC2 expression showed a significant positive correlation with stromal scores(R=0.621,P<0.001).Immunohistochemical validation confirmed that patients with high SDC2 expression had significantly better overall survival(P=0.021).Multivariate analysis further demonstrated that SDC2 remained an independent protective prognostic factor(HR=0.469,95%CI:0.226-0.974,P=0.042).In addition,a trend toward reduced infiltration of CD68+macrophages was observed in the SDC2 high-expression group.Conclusion SDC2 serves as an independent favorable prognostic biomarker in DLBCL,with higher expression associated with prolonged overall survival.Its prognostic signifi-cance may be related to modulation of the tumor microenvironment,particularly through effects on stromal components.

田荣乐;付永亮;崔菲菲;叶振邦;黄文亭

国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院病理科(北京 100021)国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院病理科(北京 100021)深圳大学医学部(广东 深圳 518060)国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院病理科(北京 100021)国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院病理科(北京 100021)

医药卫生

弥漫性大B细胞淋巴瘤多配体蛋白聚糖-2预后肿瘤微环境

diffuse large B-cell lymphomaSyndecan-2prognosistumor microenvironment

《广东医学》 2026 (5)

681-687,7

深圳市"医疗卫生三名工程"项目(SZSM202411001)

10.13820/j.cnki.gdyx.20254239

评论